OPB-111077

N/A

Report date: 2025/03/28 15:48:49
NME

Base Information

Drug NameOPB-111077
Drug Alias NameOPB-111077OPC-317
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transduction pathway inhibitorsSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsSolid tumoursNasopharyngeal CarcinomaCarcinoma, Hepatocellular +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeSpain +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer Center At Thomas Jefferson UniversityOtsuka America Pharmaceutical IncOtsuka Pharmaceutical Co Ltd
Inactive CompaniesOtsuka Pharmaceutical Development & Commercialization IncKorea Otsuka Pharmaceutical Co Ltd
Active IndicationsLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursNasopharyngeal CarcinomaCarcinoma, Hepatocellular +[4] 

Other Information

ATC CodeN/A
Related LinksN/A